Clinical Trials
9 trialsNCT01428635 2023-09-26
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT01168921 2023-03-23
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01957176 2022-12-30
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Phase 4 Completed
NCT02323178 2021-04-20
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
Groupe Francophone des Myelodysplasies
Phase 1/2 Completed
NCT01656252 2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2 Terminated
NCT01890746 2019-09-11
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Novartis
Phase 2 Completed
NCT03701217 2018-10-09
Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT01440374 2017-06-05
ASPIRE
Novartis
Phase 2 Completed
NCT01397149 2015-05-28
Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)
University of Ulm
Phase 1/2 Terminated